Literature DB >> 7583381

Abnormalities of chromosome band 11q23 and the MLL gene in pediatric myelomonocytic and monoblastic leukemias. Identification of the t(9;11) as an indicator of long survival.

J A Martinez-Climent1, R Espinosa, M J Thirman, M M Le Beau, J D Rowley.   

Abstract

PURPOSE AND METHODS: We reviewed the cytogenetic pattern of the malignant cells in 36 patients who were < 20 years of age and who had M4 and M5 leukemias, excluding M4Eo cases with inv(16). We performed fluorescence in situ hybridization (FISH) and molecular studies to determine the actual incidence of 11q23/MLL abnormalities in these patients.
RESULTS: Eighteen patients had 11q23 translocations or insertions detected by cytogenetic analysis (15 cases) or by FISH (3 cases); 10 patients had t(9;11), all of whom had M5a. Eight patients had other 11q23 translocations or insertions not involving chromosome 9[t(11q23)] (four each had M4 or M5 leukemias). Eighteen cases with M4/M5 did not have 11q23 abnormalities. MLL rearrangements were found in all patients with translocations or insertions of 11q23 who were studied. Clinically, children with t(9;11) were indistinguishable from other patients with M4-M5 leukemias. In contrast, the t(11q23) group was characterized by extreme hyperleukocytosis, CNS disease, and skin involvement. Patients with the t(9;11) had a better outcome when compared with patients in the t(11q23) group (EFS +/- SE at 3 years, 56 +/- 17% versus 10 +/- 10%, p = 0.04), and to all the remaining children with M4-M5 leukemias (p = 0.04).
CONCLUSIONS: The combination of cytogenetic, FISH, and molecular analysis provides a highly sensitive strategy for detection of 11q23/MLL gene rearrangements in childhood M4-M5 leukemias. Our more precise classification of these patients allows a more accurate correlation with outcome. The favorable prognostic significance of the t(9;11) should be confirmed in prospective studies including a larger number of children as well as adults.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7583381     DOI: 10.1097/00043426-199511000-00001

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  5 in total

Review 1.  Successful outcome of mismatched hematopoietic stem cell transplantation from a related donor in an infant with acute lymphoblastic leukemia and 9;11 translocation: case report and review of the literature.

Authors:  Junichi Kitazawa; Chikako Tono; Kiminori Terui; Naoko Kinukawa; Megumi Oda; Keiichi Isoyama; Eiichi Ishii; Etsuro Ito
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

2.  Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation.

Authors:  Courtney D DiNardo; Guilin Tang; Naveen Pemmaraju; Sa A Wang; Allison Pike; Guillermo Garcia-Manero; Jorge Cortes; Carlos Bueso-Ramos; Hagop M Kantarjian
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-06-21

3.  Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A.

Authors:  Marius Bill; Krzysztof Mrózek; Jessica Kohlschmidt; Ann-Kathrin Eisfeld; Christopher J Walker; Deedra Nicolet; Dimitrios Papaioannou; James S Blachly; Shelley Orwick; Andrew J Carroll; Jonathan E Kolitz; Bayard L Powell; Richard M Stone; Albert de la Chapelle; John C Byrd; Clara D Bloomfield
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-05       Impact factor: 11.205

Review 4.  Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia.

Authors:  Soheil Meshinchi; Franklin O Smith; Robert J Arceci
Journal:  Curr Oncol Rep       Date:  2003-11       Impact factor: 5.075

Review 5.  Straight to the Point-The Novel Strategies to Cure Pediatric AML.

Authors:  Monika Lejman; Izabela Dziatkiewicz; Mateusz Jurek
Journal:  Int J Mol Sci       Date:  2022-02-10       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.